Inclusion Criteria:

1. Patient or family able and willing to give informed consent.
2. Subjects with metastatic cancer to the brain who have failed at least one conventional therapy (surgery, stereotactic radiosurgery, and/or whole brain radiotherapy). Failure is defined as local recurrence or failure of the previously treated lesion and will be determined by the treating surgeon based on a review of patient history and imaging.
3. Tumor size </= 3.0 cm in largest diameter.
4. MR imaging is not contraindicated for the patient
5. Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as determined by the treating surgeon.
6. Able and willing to attend all study visits.
7. Karnofsky Performance Scale score >/=70 for patients over the age of 15.
8. Lansky Play Scale>/=70 for patients 15 years of age or younger.

Exclusion Criteria:

1. Patients or family unwilling or unable to give written consent.
2. Patients who cannot physically fit in, or are too heavy for, the BrainSUITE® MRI scanner
3. Patients with contra-indications to MRI imaging, such as, but not limited to, pacemakers or defibrillators, non-compatible aneurysm clips, shrapnel, or other internal ferromagnetic objects
4. Known sensitivity to gadolinium-DTPA
5. Based on Treatment Planning Imaging (MR and/or CT) done on the day of treatment: -Brain edema and/or mass effect that causes midline shift or shift in wall of ventricle of more than 5 mm. -Lesions localized in the brain stem or the posterior fossa. -Lesions less than 5mm from primary branches of cerebral vessels, venous sinus, hypophysis or cranial nerves. -Evidence of recent (<2 weeks) hemorrhage.
6. Symptoms and signs of increased intracranial pressure
7. Medical issues which prohibit the patient from undergoing surgery (as determined by the treating surgeon, anesthesiologist, IMPAC clinic, referring physician).
8. Patients who are unable to received corticosteroids.
9. Positive pregnancy test for women of child-bearing age.